Predicting potent drug combinations by exploiting monotherapy resistance

Project Information

COMBAT-RES

Grant agreement ID: 950293

DOI 10.3030/950293

EC signature date 17 November 2020

Start date 1 January 2021

End date 31 December 2025

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost € 1 499 991,00

EU contribution € 1 499 991,00

Coordinated by

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Germany

Publications

Peer reviewed articles (10)

Generative artificial intelligence empowers digital twins in drug discovery and clinical trials

Author(s): M Bordukova, N Makarov, R Rodriguez-Esteban, F Schmich, MP Menden
Published in: Expert Opinion on Drug Discovery, 2024, Page(s) 19 (1), 33-42, ISSN 1746-0441
Publisher: Informa Healthcare
DOI: 10.1080/17460441.2023.2273839

The impact of the cardiovascular component and somatic mutations on ageing

Author(s): Daniel Garger, Martin Meinel, Tamina Dietl, Christina Hillig, Natalie Garzorz-Stark, Kilian Eyerich, Martin Hrabě de Angelis, Stefanie Eyerich, Michael P. Menden
Published in: Aging Cell, 2023, ISSN 1474-9718
Publisher: Blackwell Publishing Inc.
DOI: 10.1111/acel.13957

Can artificial intelligence accelerate preclinical drug discovery and precision medicine?

Author(s): Ali Farnoud, Alexander J Ohnmacht, Martin Meinel, Michael P Menden
Published in: Expert Opinion on Drug Discovery, 2022, ISSN 1746-0441
Publisher: Informa Healthcare
DOI: 10.1080/17460441.2022.2090540

Oncogene-induced MALT1 protease activity drives post-transcriptional gene expression in malignant lymphomas

Author(s): Nicole Wimberger, Franziska Ober, Göksu Avar, Michael Grau, Wendan Xu, Georg Lenz, Michael P. Menden, Daniel Krappmann
Published in: Blood, 2023, ISSN 0006-4971
Publisher: American Society of Hematology
DOI: 10.1182/blood.2023021299

The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer

Author(s): Ohnmacht AJ, Stahler A, Stintzing S, Modest DP, Holch JW, Westphalen CB, Hölzel L, Schübel MK, Galhoz A, Farnoud A, Ud-Dean M, Vehling-Kaiser U, Decker T, Moehler M, Heinig M, Heinemann V, Menden MP
Published in: Nature Communications, 2023, ISSN 2041-1723
Publisher: Nature Publishing Group
DOI: 10.1038/s41467-023-41011-4

The pharmacoepigenomic landscape of cancer cell lines reveals the epigenetic component of drug sensitivity

Author(s): Alexander Joschua Ohnmacht, Anantharamanan Rajamani, Göksu Avar, Ginte Kutkaite, Emanuel Gonçalves, Dieter Saur, Michael Patrick Menden
Published in: Communications Biology, 2023, ISSN 2399-3642
Publisher: Nature
DOI: 10.1038/s42003-023-05198-y

WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice

Author(s): Maryam Ghalandary, Yuqiao Gao, Diana Amend, Ginte Kutkaite, Binje Vick, Karsten Spiekermann, Maja Rothenberg-Thurley, Klaus H. Metzeler, Anetta Marcinek, Marion Subklewe, Michael P. Menden, Vindi Jurinovic, Ehsan Bahrami, Irmela Jeremias
Published in: Blood, 2023, Page(s) 141 (8): 955–960., ISSN 0006-4971
Publisher: American Society of Hematology
DOI: 10.1182/blood.2022016411

Artificial intelligence in early drug discovery enabling precision medicine

Author(s): Fabio Boniolo, Emilio Dorigatti, Alexander J Ohnmacht, Dieter Saur, Benjamin Schubert, Michael P Menden
Published in: Expert Opinion on Drug Discovery, 2021, ISSN 1746-0441
Publisher: Informa Healthcare
DOI: 10.1080/17460441.2021.1918096

A statistical framework for assessing pharmacological response and biomarkers using uncertainty estimates

Author(s): Dennis Wang; James Hensman; Ginte Kutkaite; Tzen S Toh; Ana Galhoz; GDSC Screening Team; Jonathan R Dry; Julio Saez-Rodriguez; Mathew J Garnett; Michael P Menden; Frank Dondelinger
Published in: eLife, 2020, ISSN 2050-084X
Publisher: eLife Sciences Publications
DOI: 10.1101/2020.05.01.072983

Inferred Ancestral Origin of Cancer Cell Lines Associates with Differential Drug Response

Author(s): Phong Nguyen; Alexander J Ohnmacht; Samir Sharifli; Mathew J. Garnett; Michael P. Menden
Published in: International Journal of Molecular Sciences, 2021, ISSN 1422-0067
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/ijms221810135

Conference proceedings (2)

Refining first-line treatment decision in RAS wildtype (RAS-WT) metastatic colorectal cancer (mCRC) by combining clinical biomarkers: Results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).

Author(s): Julian Walter Holch, Alexander Ohnmacht, Sebastian Stintzing, Kathrin Heinrich, Benedikt Westphalen, Lena Weiss, Ludwig von Weikersthal, Thomas Decker, Alexander Kiani, Florian Kaiser, Tobias Heintges, Christoph Kahl, Frank Kullmann, Werner Scheithauer, Hartmut Link, Heinz-Gert Hoeffkes, Markus H Moehler, Dominik Paul Modest, Michael Menden, Volker Heinemann
Published in: Journal of Clinical Oncology, 2024, Page(s) 13-13
Publisher: American Society of Clinical Oncology
DOI: 10.1200/jco.2024.42.3_suppl.13

DNA METHYLATION PROFILING REFINES THE PROGNOSTIC CLASSIFICATION OF ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH INTENSIVE CHEMOTHERAPY

Author(s): Vosberg, S.; Ohnmacht, A.; Moser, C.; Arneth, A.; Jurinovic, V.; Metzeler, K. H.; Sauerland, M. C.; Görlich, D.; Berdel, W. E.; Braess, J.; Amler, S.; Krug, U.; Hiddemann, W.; Spiekermann, K.; Oakes, C. C.; Menden, M. P.; Herold, T.; Greif, P. A.
Published in: HemaSphere, 2022, ISSN 2572-9241
Publisher: Wiley
DOI: 10.1097/01.hs9.0000844804.00811.c6